RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide
2010-01-01 Coral, S; Sigalotti, L; Parisi, G; Colizzi, F; Fratta, E; Nicolay, Hjm; Taverna, P; Maio, M
Immunomodulatory activity of SGI-110, a secon generation hypometilating agent
2013-01-01 Maio, M; Choy, G; Covre, A; Parisi, G; Nicolay, H; Fratta, E; Fonsatti, E; Sigalotti, L; Coral, ; S Taverna, P; Azab, M
Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma
2010-01-01 Wolchok, Jd; Weber, Js; Hamid, O; Lebbe, C; Maio, M; Schadendorf, D; de Pril, V; Ibrahim, R; Hoos, A; O'Day, Sj
IPILIMUMAB IN PRETREATED METASTATIC UVEAL MELANOMA PATIENTS: SAFETY AND CLINICAL EFFICACY
2009-01-01 Danielli, R; Queirolo, P; Testori, A; Plummer, R; Razis, E; Sileni Chiarion, V; Calabrò, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy
2009-01-01 Danielli, R; Queirolo, P; Testori, A; Plummer, R; Razi, E; Sileni Chiarion, V; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients
2009-01-01 Di Giacomo, A; Danielli, R; Calabrò, L; Guidoboni, M; Miracco, C; Biagioli, M; Mazzei, M; Altomonte, Maresa; Maio, M
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients
2009-01-01 DI GIACOMO, ANNA MARIA; Danielli, R; Calabro, L; Bertocci, E; Nannicini, C; Miracco, C; Biagioli, M; Mazzei, Ma; Altomonte, M; Maio, M
IPILIMUMAB-MEDIATED PATTERNS OF RESPONSE IN PATIENTS WITH PRETREATED, ADVANCED MELANOMA
2008-01-01 Harmankaya, K; Pehamberger, H; Hoos, A; Ibrahim, R; O'Day, S; Hamid, O; Wolchok, J; Humphrey, R; Maio, M
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients
2009-01-01 Di Giacomo, A. M.; Danielli, R.; Calabro, L.; Bertocci, E.; Nannicini, C.; Miracco, C.; Biagioli, M.; Mazzei, M. A.; Altomonte, M.; Maio, M.
Levels of HLA-class I, -A, -B, antigens, beta(2)mu, ICAM-1 and LFA-3 do not correlate with lysis of melanoma cells induced by autologous and allogeneic NK and LAK cells.
1996-01-01 Fonsatti, E; Coral, S; Cattarossi, I; Cattelan, A; Gasparollo, A; Altomonte, M; Maio, M
Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
---|---|---|---|---|
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide | 1-gen-2010 | Coral, S; Sigalotti, L; Parisi, G; Colizzi, F; Fratta, E; Nicolay, Hjm; Taverna, P; Maio, M | - | |
Immunomodulatory activity of SGI-110, a secon generation hypometilating agent | 1-gen-2013 | Maio, M; Choy, G; Covre, A; Parisi, G; Nicolay, H; Fratta, E; Fonsatti, E; Sigalotti, L; Coral, ; S Taverna, P; Azab, M | - | |
Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma | 1-gen-2010 | Wolchok, Jd; Weber, Js; Hamid, O; Lebbe, C; Maio, M; Schadendorf, D; de Pril, V; Ibrahim, R; Hoos, A; O'Day, Sj | - | |
IPILIMUMAB IN PRETREATED METASTATIC UVEAL MELANOMA PATIENTS: SAFETY AND CLINICAL EFFICACY | 1-gen-2009 | Danielli, R; Queirolo, P; Testori, A; Plummer, R; Razis, E; Sileni Chiarion, V; Calabrò, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M | - | |
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy | 1-gen-2009 | Danielli, R; Queirolo, P; Testori, A; Plummer, R; Razi, E; Sileni Chiarion, V; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M | - | |
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients | 1-gen-2009 | Di Giacomo, A; Danielli, R; Calabrò, L; Guidoboni, M; Miracco, C; Biagioli, M; Mazzei, M; Altomonte, Maresa; Maio, M | - | |
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients | 1-gen-2009 | DI GIACOMO, ANNA MARIA; Danielli, R; Calabro, L; Bertocci, E; Nannicini, C; Miracco, C; Biagioli, M; Mazzei, Ma; Altomonte, M; Maio, M | - | |
IPILIMUMAB-MEDIATED PATTERNS OF RESPONSE IN PATIENTS WITH PRETREATED, ADVANCED MELANOMA | 1-gen-2008 | Harmankaya, K; Pehamberger, H; Hoos, A; Ibrahim, R; O'Day, S; Hamid, O; Wolchok, J; Humphrey, R; Maio, M | - | |
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients | 1-gen-2009 | Di Giacomo, A. M.; Danielli, R.; Calabro, L.; Bertocci, E.; Nannicini, C.; Miracco, C.; Biagioli, M.; Mazzei, M. A.; Altomonte, M.; Maio, M. | - | |
Levels of HLA-class I, -A, -B, antigens, beta(2)mu, ICAM-1 and LFA-3 do not correlate with lysis of melanoma cells induced by autologous and allogeneic NK and LAK cells. | 1-gen-1996 | Fonsatti, E; Coral, S; Cattarossi, I; Cattelan, A; Gasparollo, A; Altomonte, M; Maio, M | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Contributo su Rivista 67
- 1 Contributo su Rivista::1.5 Abstract in rivista 67
Data di pubblicazione
- 2010 - 2020 28
- 2000 - 2009 31
- 1995 - 1999 8
Rivista
- ANNALS OF ONCOLOGY 15
- JOURNAL OF CLINICAL ONCOLOGY 11
- EUROPEAN JOURNAL OF CANCER 7
- EUROPEAN JOURNAL OF CANCER. SUPPLEMENT 7
- JOURNAL OF IMMUNOTHERAPY 5
- CELLULAR ONCOLOGY 3
- HUMAN IMMUNOLOGY 3
- JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 3
- ASIA PACIFIC JOURNAL OF CLINICAL ONCOLOGY 2
- JOURNAL OF CLINICAL ONCOLOGY 2
Keyword
- ipilimumab 3
- melanoma 2
- brain metastases 1
- fotemustine 1
- guadecitabina 1
- guadecitabine 1
- nivolumab 1
Lingua
- eng 41
Accesso al fulltext
- no fulltext 60
- reserved 4
- open 3
Appartenenza
- Dipartimento di Biotecnologie Mediche 4
- Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze 67